Sandro Wealth Management LLC Buys Shares of 6,627 HCA Healthcare, Inc. $HCA

Key Points

• Sandro Wealth Management bought 6,627 HCA Healthcare shares worth approximately $2.584 million, making HCA about 1.9% of its portfolio. Institutional investors collectively own 62.73% of the stock.
• HCA reported quarterly EPS of $7.59, slightly above estimates, while revenue reached $20.23 billion—up 8.7% year over year and ahead of expectations.
• The company declared a quarterly dividend of $0.78 per share, or $3.12 annualized, representing a 0.8% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $465.59.

Sandro Wealth Management LLC purchased a new position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,627 shares of the company's stock, valued at approximately $2,584,000. HCA Healthcare accounts for about 1.9% of Sandro Wealth Management LLC's investment portfolio, making the stock its 18th biggest position.

Other hedge funds have also recently made changes to their positions in the company. Sumitomo Life Insurance Co. lifted its position in shares of HCA Healthcare by 1.0% during the 4th quarter. Sumitomo Life Insurance Co. now owns 2,026 shares of the company's stock valued at $946,000 after buying an additional 20 shares during the last quarter. MJP Associates Inc. ADV raised its stake in HCA Healthcare by 2.9% in the 4th quarter. MJP Associates Inc. ADV now owns 749 shares of the company's stock valued at $350,000 after acquiring an additional 21 shares during the period. Cary Street Partners Investment Advisory LLC boosted its position in HCA Healthcare by 7.5% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 300 shares of the company's stock worth $140,000 after purchasing an additional 21 shares during the period. Anchyra Partners LLC raised its position in shares of HCA Healthcare by 3.7% in the first quarter. Anchyra Partners LLC now owns 587 shares of the company's stock valued at $278,000 after purchasing an additional 21 shares during the period. Finally, Plato Investment Management Ltd boosted its holdings in HCA Healthcare by 0.6% in the 4th quarter. Plato Investment Management Ltd now owns 3,908 shares of the company's stock worth $1,833,000 after buying an additional 22 shares during the period. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $404.61 on Friday. The firm has a fifty day moving average of $393.41 and a 200 day moving average of $446.80. HCA Healthcare, Inc. has a 52-week low of $353.99 and a 52-week high of $556.52. The firm has a market capitalization of $87.60 billion, a PE ratio of 13.55, a price-to-earnings-growth ratio of 1.40 and a beta of 1.10.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings data on Friday, July 24th. The company reported $7.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $7.56 by $0.03. The firm had revenue of $20.23 billion during the quarter, compared to analysts' expectations of $19.76 billion. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The company's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business earned $6.84 EPS. On average, sell-side analysts forecast that HCA Healthcare, Inc. will post 29.47 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 16th will be paid a dividend of $0.78 per share. The ex-dividend date of this dividend is Wednesday, September 16th. This represents a $3.12 annualized dividend and a dividend yield of 0.8%. HCA Healthcare's dividend payout ratio (DPR) is 10.45%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HCA. Oppenheimer dropped their target price on HCA Healthcare from $520.00 to $485.00 and set an "outperform" rating on the stock in a research report on Monday, July 27th. UBS Group decreased their price objective on HCA Healthcare from $635.00 to $579.00 and set a "buy" rating on the stock in a research note on Monday, July 27th. Deutsche Bank Aktiengesellschaft set a $476.00 target price on HCA Healthcare in a report on Monday, July 27th. Weiss Ratings downgraded shares of HCA Healthcare from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, June 9th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $435.00 price objective on shares of HCA Healthcare in a research note on Monday, July 27th. Fourteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $465.59.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company's core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA's services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source